Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of the fiscal period ended Tuesday, December 31, 2024.
Reported annual fiscal-period values; no daily interpolation.
PEG RATIO
N/A
PEG RATIO AVG TTM
N/A
PEG RATIO AVG 3Y
1.20
PEG RATIO AVG 5Y
0.80
PEG RATIO AVG 10Y
0.81
PEG RATIO AVG 15Y
1.05
PEG RATIO AVG 20Y
1.38
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$22.03B
PEG Ratio
1.16
TTM Avg
0.84
3Y Avg
0.59
5Y Avg
0.59
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Viatris Inc. (VTRS) | $20.55B | N/A | N/A | 1.20 | 0.80 |
| United Therapeutics Corporation (UTHR)vs › | $22.03B | 1.16 | 0.84 | 0.59 | 0.59 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $18.99B | N/A | 0.07 | 1.03 | 0.84 |
| Moderna, Inc. (MRNA)vs › | $22.32B | N/A | 0.18 | 0.14 | 0.14 |
| STERIS plc (STE)vs › | $22.68B | 1.03 | 0.80 | 0.61 | 0.61 |
| BioNTech SE (BNTX)vs › | $23.16B | N/A | 0.23 | 0.12 | 0.12 |
| Hologic, Inc. (HOLX)vs › | $16.97B | N/A | 0.30 | 0.22 | 1.94 |
| Incyte Corporation (INCY)vs › | $24.28B | 0.73 | 0.00 | 0.16 | 0.24 |
| Medpace Holdings, Inc. (MEDP)vs › | $16.41B | 1.82 | 1.22 | 1.14 | 1.18 |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.72B | 33.99 | 33.99 | 32.78 | 16.88 |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.02 |
| 2021-12-31 | 2.38 |
| 2020-12-31 | 0.00 |
| 2017-12-30 | 0.85 |
| 2014-12-30 | 0.43 |
| 2013-12-30 | 4.56 |
| 2012-12-31 | 0.77 |
| 2011-12-31 | 0.21 |
| 2010-12-31 | 0.25 |
| 2008-12-31 | 0.17 |
| 2006-03-31 | 5.56 |
